ArticleBMC pediatrics2026
Fibroblast growth factor 21 and growth differentiation factor 15 as biomarkers for oxidative stress in children with methylmalonic acidemia.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Disturbances of Mitochondrial Functions and Oxidative Stress Induction in Methylmalonic and Propionic Acidemias: A Critical Role for Metabolite Accumulation.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMethylmalonic acidemia (MMA) is a rare autosomal recessive inborn error of metabolism commonly presenting in infancy with episodes of metabolic acidosis that can lead to considerable morbidity and early mortality. Oxidative stress is a major aspect in the pathogenesis of MMA. We aimed to evaluate the clinical utility of fibroblast growth factor 21 (FGF21) and growth differentiation factor 15 (GDF15) and correlate their levels with established biomarkers of oxidative stress, such as reduced glutathione (GSH) and reduced/oxidized (GSH/GSSG) glutathione ratio in MMA children in a clinical setting.
methodsNineteen MMA pediatric patients (median 5.7; IOR 2.9–7.3 years) were recruited. Thirty age and sex matched healthy children were further recruited as a comparator group. Total glutathione, reduced glutathione, FGF21 and GDF15 were assayed for both cohorts.
resultsTotal and reduced glutathione were significantly reduced in MMA patients compared to controls (P < 0.001 for both), while FGF21 and GDF15 were significantly elevated (P = 0.037 and < 0.001, respectively). Both FGF21 and GDF15 had a significant negative correlation with GSH/GSSG ratio (r=–0.256; P = 0.038 and r=–0.367; P = 0.005, respectively); however, only GDF15 had a negative correlation with both total and reduced glutathione (r=–0.443; P < 0.001 and r=–0.459; P < 0.001, respectively). GDF15 had a better performance in the ROC curve analysis; AUC = 0.805 vs. 0.668 for FGF21, while FGF21 was a significant predictor of eGFR in the linear regression analysis.
conclusionsFGF21 and GDF15 were both significantly increased in the studied MMA pediatric patients and had strong correlations with established oxidative stress biomarkers. Since both are more stable during storage and easier to assay than glutathione based indicators, their use as candidate biomarkers for oxidative stress in MMA children can be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.